Other languages Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.061 ^AUD	+2.89%		-28.24%	-23.75%

Apr. 16	Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	MT
Mar. 27	Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II	Mar. 27
Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3%	Mar. 26
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial	Jan. 17
Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US	Jan. 17
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3%	Dec. 04
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 20
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate	23-10-18
Amplia Therapeutics Gets Nod to Name Drug AMP945 Narmafotinib	23-06-23
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30
Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt	23-05-29
Amplia Therapeutics to Enter Research Collaboration with CSIRO; Shares Rise 7%	23-05-21
Amplia Therapeutics Advances Clinical Trial for Pancreatic Cancer Inhibitor Drug	23-05-09
Amplia Therapeutics Doses First Patient for Third Cohort of Pancreatic Cancer Trial; Shares Rise 6%	23-04-18
Amplia Therapeutics Limited Announces Completion of Enrolment of the Second Cohort of Patients in the Ongoing Phase 1b/2a ACCENT Clinical Trial in Frontline Patients with Pancreatic Cancer	23-02-27
Amplia Therapeutics Limited Announces First Patient Recruited to Cohort 2 of Accent Trial in Pancreatic Cancer	23-01-31
Amplia Therapeutics Secures Approval for Dose Escalation Stage of Pancreatic Cancer Trial	23-01-11
Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945	23-01-10
Amplia Therapeutics Enrols First Set of Patients in Clinical Trial of Pancreatic Cancer Treatment	22-11-29
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-17
Amplia Therapeutics Appoints Managing Director and CEO	22-11-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Other languages

Filters